BRAF and melanoma: After demonstrating that treatment with a BRAF inhibitor leads to the suppression of PLK1 in susceptible but not in resistant cells, we reanalyzed the published dataset (GSE50509) of melanoma tumor samples from patients before therapy and at the time of tumor progression during dabrafenib therapy to determine a possible correlation between BRAFi (dabrafenib) response and PLK1 expression.